Vital Statistics
| Class |
Ticker |
CUSIP |
Fund Number |
| Investor |
BIPIX |
743185480 |
043 |
| Service |
BIPSX |
743185472 |
073 |
Inception Date for all share classes is
6/19/2000
NAV
as of 2/3/2012
|
Class
|
NAV
|
% Change
|
$ Change
|
|
Investor
|
$75.35
|
2.24%
|
$1.65
|
|
Service
|
$67.35
|
2.25%
|
$1.48
|
Historical NAVs
Investor Class
Service Class
ObjectiveThe Biotechnology UltraSector ProFund seeks daily investment results, before fees and expenses, that are 1.5x the return of the Dow Jones U.S. BiotechnologySM Index (the "Index") for a single day.
Dow Jones U.S. Biotechnology Index
The Index (Bloomberg symbol: DJUSBT) measures the performance of the biotechnology sector of the U.S. equity market. Component companies engage in research and development of biological substances for drug discovery and diagnostic development. These companies derive most of their revenue from the sale or licensing of drugs and diagnostic tools. It is not possible to invest directly in an index.ex.
Index (as of 12/31/2011)
Top 10 Index Companies
|
Name
|
Weight
|
|
Amgen Inc.
|
26.90%
|
|
Celgene Corp.
|
14.69%
|
|
Gilead Sciences Inc.
|
14.44%
|
|
Biogen Idec Inc.
|
12.69%
|
|
Alexion Pharmaceuticals Inc.
|
6.21%
|
|
Life Technologies Corp.
|
3.35%
|
|
Vertex Pharmaceuticals Inc.
|
3.23%
|
|
Regeneron Pharmaceuticals Inc.
|
1.95%
|
|
BioMarin Pharmaceutical Inc.
|
1.84%
|
|
Illumina Inc.
|
1.78%
|
Total Index Companies
27
Average Index Market Capitalization
7.81 billion
Fund Statistics
|
Limits On Exchanges
|
None
|
|
Minimum Investment
|
Individual Investor
|
$15,000
|
Financial Professionals
|
$5,000
|
All data, unless otherwise noted, is as of 12/31/2011 and for Investor Class Shares only and is subject to change.
Narrowly focused investments typically exhibit higher volatility.
|